Go to the list of all blogs
Dem Sem's Avatar
published in Blogs
Apr 10, 2023
Greenbrier Companies (The) (GBX, $30.21) is expected to report earnings to fall+908% to 50 cents per share on April 10

Greenbrier Companies (The) (GBX, $30.21) is expected to report earnings to fall+908% to 50 cents per share on April 10

Greenbrier Companies (The) (GBX, $30.21) is set to report earnings on April 10, and the expectations are that earnings will fall by a significant 908% to 50 cents per share. This news has already impacted the stock's performance, as GBX moved below its 50-day moving average on April 05, 2023, indicating a change from an upward trend to a downward trend.

This shift in trend is concerning for investors who have been holding onto the stock in hopes of continued growth. In fact, historical data shows that in 28 of 34 similar past instances, the stock price decreased further within the following month. This means that the odds of a continued downward trend are 82%, making it more likely that the stock price will continue to decrease rather than recover in the near term.

As a technical analyst, it's important to consider other key indicators in addition to the moving average to get a better sense of the stock's overall performance. For example, looking at GBX's Relative Strength Index (RSI) can provide insight into whether the stock is oversold or overbought. Currently, GBX's RSI is at 30.55, indicating that the stock is oversold and potentially undervalued. However, given the recent trend shift and the expected earnings report, this oversold condition may not be enough to reverse the downward trend.

Additionally, monitoring GBX's trading volume can provide insights into investor sentiment. If trading volume is increasing alongside the downward trend, it could indicate a significant bearish sentiment and further price drops may be likely. Conversely, if trading volume decreases and stabilizes, it could indicate that the stock is reaching a floor and may start to recover.

The expected earnings report for Greenbrier Companies (The) (GBX) is a significant indicator that the stock's performance will shift from an upward trend to a downward trend. The historical data indicates that the odds of a continued downward trend are high, and other key indicators such as the RSI and trading volume suggest that this trend may persist in the near term. As always, investors should carefully consider their risk tolerance and investment goals before making any decisions about buying or selling GBX.

Related Ticker: GBX

Contributor

Dem Sem's AvatarDem Sem|Expert

GBX sees its 50-day moving average cross bullishly above its 200-day moving average

The 50-day moving average for GBX moved above the 200-day moving average on July 29, 2026. This could be a long-term bullish signal for the stock as the stock shifts to an upward trend.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Stochastic Oscillator demonstrated that the ticker has stayed in the oversold zone for 1 day, which means it's wise to expect a price bounce in the near future.

The 10-day moving average for GBX crossed bullishly above the 50-day moving average on July 21, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In of 14 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are .

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where GBX advanced for three days, in of 304 cases, the price rose further within the following month. The odds of a continued upward trend are .

GBX may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

The Aroon Indicator entered an Uptrend today. In of 248 cases where GBX Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .

Bearish Trend Analysis

The Momentum Indicator moved below the 0 level on August 05, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on GBX as a result. In of 76 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .

The Moving Average Convergence Divergence Histogram (MACD) for GBX turned negative on July 31, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 44 similar instances when the indicator turned negative. In of the 44 cases the stock turned lower in the days that followed. This puts the odds of success at .

GBX moved below its 50-day moving average on August 06, 2026 date and that indicates a change from an upward trend to a downward trend.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where GBX declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

Fundamental Analysis (Ratings)

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: GBX's P/B Ratio (0.929) is slightly lower than the industry average of (3.907). P/E Ratio (13.970) is within average values for comparable stocks, (22.242). GBX's Projected Growth (PEG Ratio) (0.000) is very low in comparison to the industry average of (2.595). Dividend Yield (0.028) settles around the average of (0.018) among similar stocks. GBX's P/S Ratio (0.571) is slightly lower than the industry average of (3.884).

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating fairly steady price growth. GBX’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. GBX’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 60, placing this stock worse than average.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

Notable companies

The most notable companies in this group are Union Pacific Corp (NYSE:UNP), CSX Corp (NASDAQ:CSX), Norfolk Southern Corp (NYSE:NSC).

Industry description

The Railroad industry includes passenger and freight transportation services along rail lines. This also includes companies that provide maintenance and switching duties as part of rail services. Within North America, the industry is largely dominated by some large operators. Several short-line railroads serve regional and local routes. Union Pacific Corporation, Canadian National Railway Company, and CSX Corporation are some of the prominent names in the business. The railroad business is relatively cyclical; economic expansion boost the freight services in particular, while economic stagnation often dampens transportation demand.

Market Cap

The average market capitalization across the Railroads Industry is 46.04B. The market cap for tickers in the group ranges from 320 to 174.14B. UNP holds the highest valuation in this group at 174.14B. The lowest valued company is URAL at 320.

High and low price notable news

The average weekly price growth across all stocks in the Railroads Industry was 2%. For the same Industry, the average monthly price growth was 2%, and the average quarterly price growth was 6%. RVSN experienced the highest price growth at 23%, while TRN experienced the biggest fall at -4%.

Volume

The average weekly volume growth across all stocks in the Railroads Industry was -36%. For the same stocks of the Industry, the average monthly volume growth was 11% and the average quarterly volume growth was -43%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 70
P/E Growth Rating: 34
Price Growth Rating: 46
SMR Rating: 60
Profit Risk Rating: 60
Seasonality Score: -38 (-100 ... +100)
View a ticker or compare two or three
GBX
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
A.I.Advisor
published price charts
Last 5 trading days
A.I. Advisor
published General Information

General Information

a manufacturer of and distributes railcars and related transportation equipment

Industry Railroads

Profile
Details
Industry
Trucks Or Construction Or Farm Machinery
Address
One Centerpoint Drive
Phone
+1 503 684-7000
Employees
13800
Web
https://www.gbrx.com
Interact to see
Advertisement
Novartis (NVS) reports Q4/FY 2025 earnings on February 4, 2026, with consensus calling for ~$1.99 EPS on ~$13.7 billion in revenue. Sanofi (SNY) delivered strong FY 2025 results on January 29, reporting €43.6 billion in sales (+9.9% CER) and 15% business EPS growth.
Novo Nordisk (NVO) reports Q4 2025 earnings on February 4, 2026, with consensus estimates of $11.96 billion in revenue and $0.89 EPS, reflecting a moderation in GLP-1 growth. Eli Lilly (LLY) is expected to report around the same time, with projections of $17.87 billion in revenue and $6.99 EPS, driven by continued volume gains from Mounjaro and Zepbound.
MUFG is expected to report Q3 FY2026 EPS of about $0.30, broadly in line with its recent pattern of earnings beats.
Banco Santander (SAN) reports Q4 2025 earnings on February 4, 2026, following record nine-month attributable profit of €10.3 billion, up 11% year over year.
Uber (UBER) reports Q4 2025 earnings on February 4, 2026, with consensus estimates of $0.78 EPS and $14.32 billion in revenue, up about 20% year over year.
Qualcomm’s Q1 FY2026 report, covering the period ended December 28, 2025, arrives amid a pivotal shift in the semiconductor landscape. While handset growth moderates, the company is expanding in automotive, IoT, and AI-enabled devices.
UBS Group AG reports Q4 2025 earnings on February 4, 2026, with consensus EPS ranging $0.25–$0.67 and revenue around $11.62 billion, down YoY. HSBC Holdings plc reports Q4 earnings on February 25, 2026, with consensus EPS ~$1.57; Q3 showed resilient net interest income despite $1.4B in legal provisions.
Boston Scientific’s Q4 caps a transformative year, driven by ~15.5% organic growth from WATCHMAN, FARAPULSE electrophysiology, and MedSurg expansions. As a leader in minimally invasive devices, BSX’s results set the benchmark against Medtronic and Stryker—diversified medtech giants navigating tariffs, procedural rebounds, and innovation.
Arm, the leading provider of energy-efficient processor designs powering over 99% of smartphones and expanding into AI data centers, faces high scrutiny in Q3 FY2026 (ending Dec 31, 2025). After a strong Q2 with record royalty and licensing revenue, investors are focused on whether AI demand will continue to drive robust growth.
CME Group (CME): Q4 2025 earnings due February 4, 2026; consensus expects adjusted EPS $2.75 and revenue ~$1.6B. S&P Global (SPGI): Q4 2025 earnings due February 10, 2026; Q3 posted EPS $4.73 and 9% revenue growth, driven by Ratings, Indices, and Market Intelligence.
Datadog (DDOG) has come under pressure in recent sessions as volatility across the software sector weighs on sentiment ahead of earnings. Trading in the $108–120 range following a pullback from highs near $200, the stock reflects a disconnect between near-term market caution and resilient underlying fundamentals.
Starbucks shares have shown renewed strength in recent trading, rebounding from earlier lows within a 52-week range of $75.50 to $117.46. The recovery reflects improving comparable sales trends and a return to transaction growth, suggesting early progress from operational initiatives aimed at reconnecting with customers.
DoorDash holds a Strong Buy consensus from 33 analysts, with an average 12-month price target of $280.82, implying more than 40% upside from recent trading levels.
Amazon’s Q4 report capped a strong year marked by accelerating cloud growth, steady retail execution, and expanding advertising profitability. The results reinforced Amazon’s positioning as a core beneficiary of enterprise AI demand, particularly through AWS, while highlighting improving operating leverage across the broader business.
ConocoPhillips reported Q4 2025 adjusted EPS of $1.02, below consensus of $1.08, driven by weaker realized commodity prices.
ICE reported Q4 2025 net revenues of $2.5 billion, up 8% year-over-year, capping 20 consecutive years of record annual revenues at $9.9 billion.
Eli Lilly’s Q4 results highlight explosive growth from GLP-1 therapies, cementing leadership in obesity and diabetes. The company’s strong revenue beat and robust 2026 guidance illustrate high-growth pharma dynamics. Johnson & Johnson, in contrast, exemplifies a diversified healthcare strategy, combining pharmaceuticals, MedTech, and consumer health for steady expansion.
Eli Lilly (LLY), AbbVie (ABBV), and Merck (MRK) all reported strong Q4 2025 earnings, but the market reacted differently to each, reflecting variations in growth profiles, product concentration, and sector dynamics. AbbVie delivered Q4 revenue of $16.62 billion, up 10% year-over-year, with full-year revenue reaching $61.2 billion, an 8.6% increase. Adjusted EPS came in at $2.71, surpassing consensus, though shares dipped following the report amid ongoing Humira concerns
Novo Nordisk (NVO) reported Q4 2025 EPS of $1.02, surpassing estimates of $0.92, with revenue of $12.53B vs $11.99B expected. Full-year 2025 sales rose 10% at constant exchange rates (CER) to DKK 309B, but 2026 guidance anticipates a 5–13% decline at CER due to pricing pressures. Novartis (NVS) posted Q4 core EPS of $2.03, beating $1.99 estimates; net sales of $13.34B slightly missed consensus. FY sales grew 8%, with core EPS up 17% to $8.98.
MUFG (Mitsubishi UFJ Financial Group) posted Q3 FY2026 profits of ¥1.81 trillion, up 3.7% YoY, on track for its full-year target of ¥2.1 trillion. HSBC is set to report Q4 FY2025 earnings on Feb 25, 2026, with consensus EPS around $1.60; recent quarters showed resilient net interest income (NII) supported by Asia wealth growth.